Lindblad WJ (2008). „Considerations for Determining if a Natural Product Is an Effective Wound-Healing Agent”. International Journal of Lower Extremity Wounds7 (2), 75–81. o. DOI:10.1177/1534734608316028. PMID18483011.
Kingston W (2008. June). „Irish contributions to the origins of antibiotics”. Irish journal of medical science177 (2), 87–92. o. DOI:10.1007/s11845-008-0139-x. PMID18347757.
Limbird LE (2004. December). „The receptor concept: a continuing evolution”. Mol. Interv.4 (6), 326–36. o. DOI:10.1124/mi.4.6.6. PMID15616162.
Bosch F, Rosich L (2008). „The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize”. Pharmacology82 (3), 171–9. o. DOI:10.1159/000149583. PMID18679046. PMC2790789.
Fleming A (1980). „Classics in infectious diseases: on the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae by Alexander Fleming, Reprinted from the British Journal of Experimental Pathology 10:226-236, 1929”. Rev. Infect. Dis.2 (1), 129–39. o. DOI:10.1093/clinids/2.1.129. PMID6994200. PMC2566493.[halott link]
Slama TG, Amin A, Brunton SA, et al. (2005. July). „A clinician's guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria”. Am. J. Med.118 Suppl 7A, 1S–6S. o. DOI:10.1016/j.amjmed.2005.05.007. PMID15993671.
Andersson DI (2006. October). „The biological cost of mutational antibiotic resistance: any practical conclusions?”. Curr. Opin. Microbiol.9 (5), 461–5. o. DOI:10.1016/j.mib.2006.07.002. PMID16890008.
Baker-Austin C, Wright MS, Stepanauskas R, McArthur JV (2006. April). „Co-selection of antibiotic and metal resistance”. Trends Microbiol.14 (4), 176–82. o. DOI:10.1016/j.tim.2006.02.006. PMID16537105.
Alekshun MN, Levy SB (2007. March). „Molecular mechanisms of antibacterial multidrug resistance”. Cell128 (6), 1037–50. o. DOI:10.1016/j.cell.2007.03.004. PMID17382878.
Witte W (2004. September). „International dissemination of antibiotic resistant strains of bacterial pathogens”. Infect. Genet. Evol.4 (3), 187–91. o. DOI:10.1016/j.meegid.2003.12.005. PMID15450197.
David Tilman, Kenneth G. Cassman, Pamela A. Matson, Rosamond Naylor & Stephen Polasky: Agricultural sustainability and intensive production practices, Nature 418, 671-677 (8. August 2002), doi:10.1038/nature01014
Hawkey PM (2008. September). „The growing burden of antimicrobial resistance”. J. Antimicrob. Chemother.62 Suppl 1, i1–9. o. DOI:10.1093/jac/dkn241. PMID18684701.
Ong S, Nakase J, Moran GJ, Karras DJ, Kuehnert MJ, Talan DA (2007). „Antibiotic use for emergency department patients with upper respiratory infections: prescribing practices, patient expectations, and patient satisfaction”. Annals of emergency medicine50 (3), 213–20. o. DOI:10.1016/j.annemergmed.2007.03.026. PMID17467120.
Per H. Mygind1, Rikke L. Fischer et al.: Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungu. Nature 437, vol 7061, 2005, S. 975–80 doi:10.1038/nature04051
Peter Sass et al.: Antibiotic acyldepsipeptides activate ClpP peptidase to degrade the cell division protein FtsZ. Proceedings of the National Academy of Sciences, 2011, doi:10.1073/pnas.1110385108
Mattey M, Spencer J (2008. December). „Bacteriophage therapy--cooked goose or phoenix rising?”. Curr. Opin. Biotechnol.19 (6), 608–12. o. DOI:10.1016/j.copbio.2008.09.001. PMID18926909.
Kutateladze M, Adamia R (2008. August). „Phage therapy experience at the Eliava Institute”. Med Mal Infect38 (8), 426–30. o. DOI:10.1016/j.medmal.2008.06.023. PMID18687542.
Merril CR, Scholl D, Adhya SL (2003. June). „The prospect for bacteriophage therapy in Western medicine”. Nat Rev Drug Discov2 (6), 489–97. o. DOI:10.1038/nrd1111. PMID12776223.
Lu TK, Collins JJ (2007). „Dispersing biofilms with engineered enzymatic bacteriophage”. Proceedings of the National Academy of Sciences, USA104 (27), 11197–11202. o. DOI:10.1073/pnas.0704624104. PMID17592147. PMC1899193.
Gillor O, Kirkup BC, Riley MA (2004). „Colicins and microcins: the next generation antimicrobials”. Adv. Appl. Microbiol.54, 129–46. o. DOI:10.1016/S0065-2164(04)54005-4. PMID15251279.
Jones RL, Peterson CM, Grady RW, Kumbaraci T, Cerami A, Graziano JH (1977). „Effects of iron chelators and iron overload on Salmonella infection”. Nature267 (5606), 63–65. o. DOI:10.1038/267063a0. PMID323727.
Brock JH, Liceaga J, Kontoghiorghes GJ (2006). „The effect of synthetic iron chelators on bacterial growth in human serum”. FEMS Microbiology Letters47 (1), 55–60. o. DOI:10.1111/j.1574-6968.1988.tb02490.x.
Nacar A, Nacar E (2008). „Phagotrophic protozoa: A new weapon against pathogens?”. Medical Hypotheses70 (1), 141–142. o. DOI:10.1016/j.mehy.2007.03.037. PMID17553625.
Élelmiszer-biztonság. [2011. február 26-i dátummal az eredetiből archiválva]. (Hozzáférés: 2018. július 15.), European Food Information Council (EUFIC)
Lindblad WJ (2008). „Considerations for Determining if a Natural Product Is an Effective Wound-Healing Agent”. International Journal of Lower Extremity Wounds7 (2), 75–81. o. DOI:10.1177/1534734608316028. PMID18483011.
Forrest RD (1982. March). „Early history of wound treatment”. J R Soc Med75 (3), 198–205. o. PMID7040656. PMC1437561.
Kingston W (2008. June). „Irish contributions to the origins of antibiotics”. Irish journal of medical science177 (2), 87–92. o. DOI:10.1007/s11845-008-0139-x. PMID18347757.
Foster W, Raoult A (1974. December). „Early descriptions of antibiosis”. J R Coll Gen Pract24 (149), 889–94. o. PMID4618289. PMC2157443.
Limbird LE (2004. December). „The receptor concept: a continuing evolution”. Mol. Interv.4 (6), 326–36. o. DOI:10.1124/mi.4.6.6. PMID15616162.
Bosch F, Rosich L (2008). „The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize”. Pharmacology82 (3), 171–9. o. DOI:10.1159/000149583. PMID18679046. PMC2790789.
Fleming A (1980). „Classics in infectious diseases: on the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae by Alexander Fleming, Reprinted from the British Journal of Experimental Pathology 10:226-236, 1929”. Rev. Infect. Dis.2 (1), 129–39. o. DOI:10.1093/clinids/2.1.129. PMID6994200. PMC2566493.[halott link]
Sykes R (2001). „Penicillin: from discovery to product”. Bull. World Health Organ.79 (8), 778–9. o. PMID11545336. PMC2566502.
Slama TG, Amin A, Brunton SA, et al. (2005. July). „A clinician's guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria”. Am. J. Med.118 Suppl 7A, 1S–6S. o. DOI:10.1016/j.amjmed.2005.05.007. PMID15993671.
Andersson DI (2006. October). „The biological cost of mutational antibiotic resistance: any practical conclusions?”. Curr. Opin. Microbiol.9 (5), 461–5. o. DOI:10.1016/j.mib.2006.07.002. PMID16890008.
Baker-Austin C, Wright MS, Stepanauskas R, McArthur JV (2006. April). „Co-selection of antibiotic and metal resistance”. Trends Microbiol.14 (4), 176–82. o. DOI:10.1016/j.tim.2006.02.006. PMID16537105.
Alekshun MN, Levy SB (2007. March). „Molecular mechanisms of antibacterial multidrug resistance”. Cell128 (6), 1037–50. o. DOI:10.1016/j.cell.2007.03.004. PMID17382878.
Witte W (2004. September). „International dissemination of antibiotic resistant strains of bacterial pathogens”. Infect. Genet. Evol.4 (3), 187–91. o. DOI:10.1016/j.meegid.2003.12.005. PMID15450197.
Hawkey PM (2008. September). „The growing burden of antimicrobial resistance”. J. Antimicrob. Chemother.62 Suppl 1, i1–9. o. DOI:10.1093/jac/dkn241. PMID18684701.
Ong S, Nakase J, Moran GJ, Karras DJ, Kuehnert MJ, Talan DA (2007). „Antibiotic use for emergency department patients with upper respiratory infections: prescribing practices, patient expectations, and patient satisfaction”. Annals of emergency medicine50 (3), 213–20. o. DOI:10.1016/j.annemergmed.2007.03.026. PMID17467120.
Mattey M, Spencer J (2008. December). „Bacteriophage therapy--cooked goose or phoenix rising?”. Curr. Opin. Biotechnol.19 (6), 608–12. o. DOI:10.1016/j.copbio.2008.09.001. PMID18926909.
Kutateladze M, Adamia R (2008. August). „Phage therapy experience at the Eliava Institute”. Med Mal Infect38 (8), 426–30. o. DOI:10.1016/j.medmal.2008.06.023. PMID18687542.
Merril CR, Scholl D, Adhya SL (2003. June). „The prospect for bacteriophage therapy in Western medicine”. Nat Rev Drug Discov2 (6), 489–97. o. DOI:10.1038/nrd1111. PMID12776223.
Lu TK, Collins JJ (2007). „Dispersing biofilms with engineered enzymatic bacteriophage”. Proceedings of the National Academy of Sciences, USA104 (27), 11197–11202. o. DOI:10.1073/pnas.0704624104. PMID17592147. PMC1899193.
Gillor O, Kirkup BC, Riley MA (2004). „Colicins and microcins: the next generation antimicrobials”. Adv. Appl. Microbiol.54, 129–46. o. DOI:10.1016/S0065-2164(04)54005-4. PMID15251279.
Jones RL, Peterson CM, Grady RW, Kumbaraci T, Cerami A, Graziano JH (1977). „Effects of iron chelators and iron overload on Salmonella infection”. Nature267 (5606), 63–65. o. DOI:10.1038/267063a0. PMID323727.
Soteriadou K, Papvassiliou P, Voyiatzaki C, Boelaert J (1995). „Effects of iron chelation on the in-vitro growth of leishmania promastigotes”. The Journal of antimicrobial chemotherapy35 (1), 23–29. o. PMID7768775.
Nacar A, Nacar E (2008). „Phagotrophic protozoa: A new weapon against pathogens?”. Medical Hypotheses70 (1), 141–142. o. DOI:10.1016/j.mehy.2007.03.037. PMID17553625.
ncbi.nlm.nih.gov
Forrest RD (1982. March). „Early history of wound treatment”. J R Soc Med75 (3), 198–205. o. PMID7040656. PMC1437561.
Foster W, Raoult A (1974. December). „Early descriptions of antibiosis”. J R Coll Gen Pract24 (149), 889–94. o. PMID4618289. PMC2157443.
Bosch F, Rosich L (2008). „The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize”. Pharmacology82 (3), 171–9. o. DOI:10.1159/000149583. PMID18679046. PMC2790789.
Fleming A (1980). „Classics in infectious diseases: on the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae by Alexander Fleming, Reprinted from the British Journal of Experimental Pathology 10:226-236, 1929”. Rev. Infect. Dis.2 (1), 129–39. o. DOI:10.1093/clinids/2.1.129. PMID6994200. PMC2566493.[halott link]
Sykes R (2001). „Penicillin: from discovery to product”. Bull. World Health Organ.79 (8), 778–9. o. PMID11545336. PMC2566502.
Lu TK, Collins JJ (2007). „Dispersing biofilms with engineered enzymatic bacteriophage”. Proceedings of the National Academy of Sciences, USA104 (27), 11197–11202. o. DOI:10.1073/pnas.0704624104. PMID17592147. PMC1899193.
Antibiotics FAQ. McGill University, Canada. [2008. február 16-i dátummal az eredetiből archiválva]. (Hozzáférés: 2008. február 17.)
Élelmiszer-biztonság. [2011. február 26-i dátummal az eredetiből archiválva]. (Hozzáférés: 2018. július 15.), European Food Information Council (EUFIC)